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A B S T R A C T
In silico chemical safety assessment can support the evaluation of hazard and risk following potential exposure to
a substance. A symposium identiﬁed a number of opportunities and challenges to implement in silico methods,
such as quantitative structure-activity relationships (QSARs) and read-across, to assess the potential harm of a
substance in a variety of exposure scenarios, e.g. pharmaceuticals, personal care products, and industrial che-
micals. To initiate the process of in silico safety assessment, clear and unambiguous problem formulation is
required to provide the context for these methods. These approaches must be built on data of deﬁned quality,
while acknowledging the possibility of novel data resources tapping into on-going progress with data sharing.
Models need to be developed that cover appropriate toxicity and kinetic endpoints, and that are documented
appropriately with deﬁned uncertainties. The application and implementation of in silico models in chemical
safety requires a ﬂexible technological framework that enables the integration of multiple strands of data and
evidence. The ﬁndings of the symposium allowed for the identiﬁcation of priorities to progress in silico chemical
safety assessment towards the animal-free assessment of chemicals.
1. Introduction
In silico chemical safety assessment aims to place the evaluation of
the risks of chemical exposure on a much broader and profound
knowledge-base. It has at its heart the need for more robust, re-
producible, translatable, cheaper, rapid and ethically acceptable as-
sessment of chemicals. This topic was the main focus of a forward-
looking symposium held on 11 October 2018 at the Friedrich-
Alexander-University, Erlangen, Germany. The purpose of the sympo-
sium was to reﬂect on perspectives, opportunities and challenges in
chemical safety and to ﬁnd future directions. The key drivers for the
symposium were to investigate the use of in silico approaches in safety
assessment with a focus on quantitative structure-activity relationships
(QSARs) and read-across. Key stakeholders and contributors from the
pharmaceutical, personal care products and chemical industries, as well
as from regulatory agencies, were invited to make presentations. In
particular, the symposium enabled cross-industry discussions and an
opportunity to develop and share a vision for the next steps in this ﬁeld.
This report summarises the main ﬁndings that came from a series of
expert presentations and discussions; it is based around a number of
themes that arose concerning the on-going development of models that
will allow for animal-free chemical assessment. The main themes and
their inter-relationships are summarised in Fig. 1, with a clear emphasis
on cross-sector appreciation of the issues and means to resolve them.
2. Problem formulation
In silico techniques are used in a wide variety of scenarios within
and between industries including, but not limited to, screening, prior-
itisation, classiﬁcation and labelling, risk assessment, and product de-
velopment [1]. While there is no “one size ﬁts all” approach for in silico
modelling, and approaches must be tailored to the speciﬁc use case and
context, there are a number of common themes. One of the key themes
is the motivation of industries to adopt the “fail-fast, fail-cheap” phi-
losophy to screen out potentially hazardous molecules early in the de-
velopment process [2]. However, other speciﬁc uses of in silico methods
abound. For instance, within the pharmaceutical industry, knowledge-
based systems and QSARs are used to predict mutagenicity of impurities
as part of the ICH Harmonised Guideline M7 scheme [3,4]. At the other
end of the spectrum, cosmetics industries foresee the use of in silico
techniques as part of an ab initio approach to assess the overall impact
of a chemical. The assessment typically includes information on
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mechanisms of action, exposure, and use case scenarios, as well as the
more traditional and accepted use for toxicity prediction [5]. Increas-
ingly, attention is also being turned to consideration of formulated
products, mixtures and natural products in addition to the “traditional”
application to single substances. A number of common drivers are ap-
parent for the use of in silico approaches across the sectors relating in
part to the replacement of animal use and to more human-relevant
information oﬀering improved scientiﬁc practice. There is a clear re-
quirement for in silico modelling to cross geographical boundaries and
industrial sectors, to learn from each other and enable knowledge to be
applied eﬀectively.
Overall, while there is extensive development of new in silico
methods, there is an overriding need to ensure these are ﬁt for purpose.
This implies close collaboration between chemists, toxicologists, in-
formaticians and risk assessors to develop, maintain and utilise ap-
propriate models. Not only must the diﬀerent disciplines come together,
but also those scientists from industry, academia and regulatory agen-
cies must recognise the commonalities. The challenge is to respond to
the growing need for adaptable, ﬂexible and even bespoke computa-
tional workﬂows that meet the demands of industry and regulators, by
exploiting the emerging methodologies of 21st Century toxicology and
risk assessment.
3. Data
Toxicological data and information are crucial to in silico safety
assessment not only in terms of availability, but also their abundance
and quality. The current status is an increasing number of data relating
to the adverse eﬀects of chemicals which range from the results of high
content analyses to historical toxicity data across a number of publicly
and commercially available databases. There is also a wealth of (po-
tentially high quality) toxicological data buried in the archives of
business, and pharmaceutical companies in particular, which would
oﬀer great opportunities, if exploited. This has brought forward the
concept of data sharing to enable access to otherwise untapped re-
sources. It is known that data sharing requires overcoming the appre-
hension of (pharmaceutical) companies about the release of sensitive,
proprietary, preclinical data. Two international initiatives, the eTOX
and the eTRANSAFE projects, have shown how sharing data (previously
considered to be commercially sensitive) could be achieved, on a with-
cost basis, with the former project showing demonstrable success and
promise for the future [6–9]. The development of these databases from
in-house data complement other activities, such as the freely available
COSMOS DB [10], which have focussed on sharing data for non-phar-
maceutical compounds, e.g. cosmetics ingredients and fragrances.
These projects have helped identify and resolve a number of problems;
for instance, integration of data from diﬀerent sources requires the
development and implementation of ontologies and other standards –
eTOX being an example where eﬀort was made to create standardised
ontologies [11]. In this respect, the CDISC SEND format is a standard
that will facilitate the sharing of preclinical legacy data and, conse-
quently, assist the development of more reliable (in terms of not only
predictive performance, but also applicability and translatability) in
silico predictive systems.
Another recognised issue with public and private data resources
alike is ensuring and understanding the quality of the data.
Understanding data quality involves not only accurate recording and
translation of data, i.e. ensuring what is stored in the database is ac-
curate through appropriate annotation and curation, but also evalu-
ating the value and relevance of the data according to the context of use
[12]. All eﬀorts to create reliable and usable databases require expert
judgement of quality and data checking through deﬁned procedures.
Expert judgement also assists in the evaluation of data, as demonstrated
by their utility in models, and hence checking and updating of data
resources. Appreciation of data quality will enable higher conﬁdence in
models and understanding of their limitations [13].
The opportunity for the future use of toxicological data is to en-
courage and embrace data sharing, recognising all the practical and
legal problems particularly around standardisation and implementa-
tion. Techniques such as the use of honest brokers and masking of
chemical identity will enable full use of data whilst ensuring con-
ﬁdentiality. A snowball eﬀect is often seen, when one company releases
data, others are encouraged to do so. The advantages (chemical di-
versity, reliability, quality, granularity of information) clearly outweigh
the problems and costs.
4. Models
The modelling of toxicity and the use of the subsequent models
within an appropriate modelling framework is at the heart of the in
silico safety paradigm. There is an increasing variety of models to pre-
dict toxicity varying in their application from the use of structural alerts
to artiﬁcial intelligence and deep learning algorithms. This is accom-
panied by a burgeoning realisation of the need to change focus from
single standalone models to their role within frameworks that can in-
tegrate and interpret multiple strands of data and information. Of the
models available there is a currently a particular focus on read-across in
terms of identifying analogues and providing supporting data to make
better use of existing experimental toxicity data [14,15]. This is seen as
a powerful tool for data gap ﬁlling, with successes in areas such as the
completion of dossiers for REACH, although with many questions still
left unanswered, such as those relating to acceptance and the trans-
latability to humans and, for environmental risk assessment, a broader
spectrum of species. There is increasing coverage of structural alerts for
many endpoints that have previously proven diﬃcult to model [16,17]
with further work on-going.
Many exciting and novel applications are seen in modelling and
predicting “challenging” properties and endpoints. For instance, one of
the most diﬃcult aspects to predict is the formation of metabolites. To
address this, a new programme MetScore predicts Sites of Metabolism
(SoM) for Phase I and Phase II metabolic transformations. The software
is based on speciﬁcally developed radial atomic reactivity and steric
descriptors. This enables the optimisation of compounds in drug dis-
covery projects with regard to metabolic stability [18]. Other work is
Fig. 1. The main areas of opportunities and challenges identiﬁed for in silico models to support animal-free safety assessment of chemicals.
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developing better ﬁngerprints for chemical and biological similarity.
For instance, new Vectorised Phenotype Descriptors have been devel-
oped from High Content Screening FingerPrints (HCSFP) on the basis of
image analysis from cellular high content screening [19]. The HCSFPs
can be used to cluster compounds, providing diﬀerent information to
chemical similarity alone. This work enables the linkage of phenotype
to Mode of Action, with the assumption that similarity in the HCSFP
descriptors is related to activity. This method allows the user to inter-
rogate the original information, in terms of the image analyses, to re-
solve any potential queries relating to activity.
In addition to developing novel modelling tools, new schemes and
techniques for modelling are required for safety assessment in parti-
cular areas. Modelling approaches can be applied to mixtures (in the
broadest sense including co-exposures, natural products etc). The EU
EuroMix Project is developing strategies to implement in silico ap-
proaches for Cumulative Assessment Groups (used in the EU assessment
of pesticides) as part of this initiative (https://www.euromixproject.eu/
). Diﬀerent approaches can be applied to mixtures from simplistic
Thresholds of Toxicological Concern (TTC) for individual components
to establishing similarity in mode of toxic action [20]. In silico ap-
proaches can be applied at various levels to model mixture toxicity from
phenotype to organ eﬀects to mode and mechanism of action. QSAR
and molecular docking approaches have been applied to evaluate the
similarity of compounds that elicit the same mechanism of liver toxicity
as well as other eﬀects such as reproductive and developmental toxi-
city. Modelling of mixture toxicity will require the unravelling of me-
chanisms, interactions and toxicity data as well as acceptance of new
strategies and, inevitably, new criteria for acceptance.
It is, of course, the model that is central to all other issues con-
sidered in this report: while data and technologies support the eﬀort,
the model itself holds the key for application and implementation. The
opportunities and challenges for models are intrinsically linked, with
the need for proper problem formulation being required to inform
model implementation and acceptance, and vice versa. It is well known
that despite a half century of progress in QSAR, there are still many
toxicological endpoints that are diﬃcult to predict, e.g. chronic toxi-
city, developmental and reproductive toxicity [21]. It is even arguable
that some of these chronic eﬀects, involving long periods from insult-to-
injury, are not even predictable, except in probabilistic terms. In ad-
dition, there is chemical diversity both within, but more signiﬁcantly
between, industrial sectors, which raises the challenge of domain-spe-
ciﬁc or more general models. The opportunity is to provide ﬁt-for-
purpose and chemistry relevant predictive systems based on reliable,
quality assured toxicological data. New systems will need to integrate
diﬀerent types of data to address issues of similarity, from both the
chemical and biological perspective. Likewise, there is a need to con-
sider dissimilarity both in terms of read-across analogues and the use of
model applicability domains. At the moment, there are many key
questions but none more important than checking whether a compound
is within the applicability domain of a model, and knowing how to deal
with a compound outside of the domain. This is also linked to the ac-
ceptance of a prediction, i.e. when does a model cease to be suﬃciently
predictive, or when is there too much uncertainty surrounding the
prediction? Opportunities for addressing such questions arise from ap-
proaches that quantify the uncertainty of prediction (based on perfor-
mance statistics), using techniques such as Dempster-Shafer Theory to
combine uncertainties within a weight-of-evidence modelling approach
[22].
5. Technology
The models and data repositories for in silico chemical safety as-
sessment require appropriate tools for their implementation. New in-
formatics structures have enabled the linking of data and predictive
resources in tools such as ChemTunes and ToxGPS [23]. From the de-
scription of molecular properties to adverse outcomes, there are various
sophisticated means of capturing relevant information. The European
Food Safety Authority (EFSA) has taken the approach of developing
technologies and tools that will allow for the application of (Q)SAR and
read-across as well as linkage to relevant databases e.g. EFSA Open-
FoodTox [24].
The new technologies also need to incorporate progress in the un-
derstanding and modelling of the biological mechanisms from a systems
biology perspective. This will ultimately facilitate the discovery of new
targets for pharmacological interventions, and enable the design and
development of new drugs in a way that reduces the risk of the un-
desired side-eﬀects.
The opportunity is to draw together the various strands of in silico
chemical safety assessment such as chemistry, toxicology and infor-
matics into an integrated “data science” platform that allows for the
formulation of useable knowledge derived from the information and
data within the databases. Such a platform would enable decisions to be
informed by the in silico evidence. Future in silico chemical safety as-
sessment tools need to be ﬂexible and future-proof, allowing a user to
move seamlessly between diﬀerent levels of the Data-Information-
Knowledge pyramid.
6. Application and implementation
The application of models and tools in in silico chemical safety as-
sessment is intrinsically linked to the problem formulation [25]. Models
and tools must be adaptable in a business environment where markets
are global, but most regulations are regional. The implementation of in
silico chemical safety assessment requires the use of expert judgement.
To obtain a satisfactory outcome, i.e. acceptance of a prediction, gui-
dance is required – for regulatory decisions this would normally be
derived from the relevant regulatory body (e.g. guidance issued by the
European Chemicals Agency (ECHA), EFSA or the European Medicines
Agency (EMA)). Guidance needs clear practical instructions to ensure
reproducibility; this is reinforced by the necessity of clear and trans-
parent documentation to minimise subjectivity and allow for reprodu-
cibility in conducting and reporting in silico toxicology. In addition to
undertaking the predictions, there is a need to understand the un-
certainties associated with predictions and how the uncertainties can be
deﬁned and usefully applied. For instance, there is still considerable,
and often unknown, uncertainty in the source data. Case studies de-
monstrating the practical implementation of the guidance for in silico
chemical safety assessment are also helpful as an educational resource.
There is also a recognised need for capacity building of trained users
within a multidisciplinary international community [26].
Models are no longer applied in isolation to determine chemical
safety; there has been a growing global trend towards the development
and use of multiple strands of information within Integrated
Approaches to Testing and Assessment (IATA) for safety assessment
[5,27,28]. Nearly all IATA involve the use of existing data, (Q)SAR
predictions and/or read-across that are amenable to being integrated
into computational workﬂows. In addition, there is a growing trend
towards weight-of-evidence approaches that combine diﬀerent types of
predictions, e.g. for ICH M7, to reach an overall conclusion which in-
evitably involves some degree of expert judgement.
To enable safety assessment to be undertaken, there is a clear need
to include suﬃcient information about exposure, including internal
exposure. Much of this will rely on data-driven expert judgement,
supported where possible by QSARs – although it is acknowledged that
reliable QSARs are lacking for many ADME endpoints. Exposure
models, such as Physiologically Based Kinetic (PBK) models [29], will
be strengthened by including experimental data; for instance there is
great value in including in vitro data (e.g. from high throughput
screening) to strengthen models for ADME properties [30]. Diﬀerent
exposure models are required by the diﬀerent industrial sectors, e.g.
while the cosmetics industry is primarily concerned with the dermal
and inhalation routes, oral absorption is more important for the
M.T.D. Cronin et al. Computational Toxicology 10 (2019) 38–43
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pharmaceutical and food industries. The TTC approach is seen as a
simple and practical means of safety assessment based on information
on chemical structure and exposure alone [31] ; it may also assist in the
evaluation of mixtures of synthetic and natural products. There is an
increasing need to consider internal exposures to chemicals, again
through the modelling of the distribution of chemicals. Such modelling
may allow for the derivation, in the future, of reliable “internal TTC”
(iTTC) values. Since assessments of exposure and knowledge of (tox-
icologically relevant) points of departure are at the heart of modern
safety assessment, providing the modelling support to make the as-
sessments, and hence decisions, will be particularly important in areas
such as cosmetics and personal products.
From a business perspective, there must be realism with regard to
software. While transparency in modelling and frameworks is preferred,
this must be reconciled with the issues of Intellectual Property Rights
(IPR) and commercial interests to maintain a product. Transparency in
the deﬁnition of the models within commercial systems and how de-
cisions are reached is required. This is a critical aspect to avoid “black-
Fig. 2. The main challenges for in silico chemical safety assessment and their interrelationship with the opportunitiesidentiﬁed during the symposium. For the
challenges, the boxes are colour coded according to ﬁve main themes: purple – problem formulation; gold – data: red – models; green – technology; blue –
implementation, application and acceptance. The opportunities cross all the main issues identiﬁed.
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box” systems where a prediction is made but cannot be justiﬁed or
veriﬁed. There is a balance, however, to maintain the sustainability and
commercial viability in the development of models and software which
incorporates appropriate transparency while protecting the IPR of the
developer. While there are considerable advantages in using freely
available software and databases, it must be remembered that there is a
cost associated with all in silico resources. Sustainable business models
are essential across the industry that allow for free access, where ap-
propriate, for instance for training, education and increasing aware-
ness. However, to ensure the future legacy and viability of models and
resources, as well as appropriate maintenance, support and security,
there must be realism and the acceptance of cost and need for funding
on a commercial basis. Such funding will enable other aspects of im-
plementation, such as functionality (extensibility and sharing) and
versioning, to be maintained and developed.
The opportunity is for the application and implementation of safety
assessment methodologies in computational frameworks, based on a
sustainable business model. The tools need to be ﬂexible to account for
needs at the business and regulatory levels. Guidance, protocols and
training are needed to develop understanding, transparency and con-
sistency in the application of methods, and to increase the number of
trained users.
7. Acceptance
In silico chemical safety assessment must be ﬁt for purpose, which
can be interpreted as being acceptable for the speciﬁc scientiﬁc ques-
tion and use context. Acceptability is the willingness of the end-user
(e.g. regulatory assessor) to trust the model and its predictions, and thus
does not represent the sole belief of the model developer. The type and
level of acceptance required will inﬂuence how modelling is undertaken
and reported. Regulatory toxicology, to a large extent, is based on a
culture of “validation” – especially when it comes to acceptance of al-
ternative approaches over traditional animal tests. While the OECD
Principles for Validation of QSARs are intended to support the reg-
ulatory application of models, it can be diﬃcult to translate them into
an “acceptable prediction”, or what in REACH guidance is termed an
“adequate (Q)SAR Result” [32]. Much has been made of acceptance of
read-across predictions for the REACH legislation, but this is on a case-
by-case basis and cannot be guaranteed a priori. Acceptance can how-
ever be inﬂuenced by demonstrating the conﬁdence associated with a
prediction (e.g. through deﬁnition of uncertainties) as well as careful
and thorough documentation providing access to the underlying data
[33]. It is inevitable that high conﬁdence will be required in some in-
stances, e.g. risk assessment, to ensure acceptability. It is recognised
that, for good reasons, the regulatory frameworks that are the result of
the political and legislative process are designed to give a degree of
certainty and consistency to all stakeholders and therefore may lack the
mechanisms to adapt quickly to the progress made in in silico science.
This has led to frustrations on all sides and a realisation that there is a
need to optimise the process for acceptance and use of in silicomethods.
The opportunity for in silico chemical safety assessment, as a com-
munity of developers, users and evaluators, is to provide assessments of
the conﬁdence that may be associated with predictions in order to
determine their utility. Once the required level of conﬁdence is estab-
lished for a given application and context, acceptance for predictions
can be sought and case-dependent, evidence-based solutions provided.
8. Conclusions
In silico chemical safety assessment is at the conﬂuence of infor-
matics, chemistry, biology, mechanistic toxicology and regulatory sci-
ence. It provides a platform to make evidence-informed decisions which
are defensible and ﬁt-for-purpose. The challenges and related oppor-
tunities identiﬁed within the symposium are summarised in Fig. 2.
While this is not a comprehensive overview, it does provide a snapshot
of the current status of in silico chemical safety assessment. An obvious
feature is the challenge to provide a ﬂexible technologies which will
form the basis of the new modelling approaches and allow them to be
utilised appropriately and successfully.
The overriding goal of in silico chemical safety assessment is the
acceptance of a prediction for a particular purpose, while the challenges
to achieve that goal are many and varied. Key to acceptance is the
ability to provide a well-documented body of evidence meeting a de-
ﬁned level of conﬁdence and to ensure proper and appropriate use and
avoid misuse for business, political or other purposes. However, a key
remaining challenge is how to identify, quantify and consistently
communicate uncertainties (especially related to New Approach
Methodologies) – a process which is often subjective and usually per-
formed on a case-by-case basis. Other challenges faced in making in
silico scientiﬁc methods acceptable are partly technical as well as po-
litical, socio-economic and cultural [34]. Within the challenges, there
are considerable opportunities to extend the current paradigm in tox-
icology and risk assessment and bring together many disparate dis-
ciplines to strive towards animal-free, and target species relevant, as-
sessments that are broadly applicable across the globe.
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